[Prolactin secretion in Itsenko-Cushing disease patients treated with chloditan and peritol]. 1982

V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban

Prolactin secretion was studied in 46 patients with Icenko-Cushing's disease in the acute stage, at the early and late terms of the treatment with khloditan and low doses of peritol and over a period of partial and clinical remission, resultant of the treatment with khloditan and high doses of peritol. The changes in the blood prolactin concentration were determined on the empty stomach by radioimmunoassay in the presence of insulin hypoglycemia and thyroliberin injection. It was found that the prolactin basal level in the blood of patients with Icenko-Cushing's disease remained elevated at the early and late terms of the treatment with khloditan and low doses of peritol and the adenohypophyseal reactivity to stimulants did not return to normal. Khloditan and high dose peritol treatment did not induce clinical and hormonal remission of the disease but resulted in the blood prolactin basal level increase and even more pronounced decrease in the adenohypophyseal reactivity to stimulants in comparison with those of the active stage of the disease. The blood prolactin concentration in patients with clinical remission lowered down to the level, being seen before the treatment, and the reactivity to stimulants significantly improved comparatively to that of the partial remission, but did not return to normal.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008939 Mitotane A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. o,p-DDD,ortho,para-DDD,Chloditan,Chlodithane,Khloditan,Lysodren,Mytotan,ortho,para DDD
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D003533 Cyproheptadine A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Antergan,Dihexazin,Periactin,Peritol,Viternum
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1983, Farmakologiia i toksikologiia,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1966, Problemy endokrinologii i gormonoterapii,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
December 1973, Sovetskaia meditsina,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1967, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1979, Terapevticheskii arkhiv,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1985, Problemy endokrinologii,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 2015, Terapevticheskii arkhiv,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1992, Klinicheskaia meditsina,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1973, Problemy endokrinologii,
V N Slavnov, and E V Luchitskiĭ, and I V Komissarenko, and A K Cheban
January 1990, Fel'dsher i akusherka,
Copied contents to your clipboard!